GlaxoSmithKline PLC found using ticker (GSK) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 52.5 and 45.94 calculating the mean target price we have 49.81. Now with the previous closing price of 44.37 this indicates there is a potential upside of 12.3%. There is a 50 day moving average of 44.04 and the 200 day MA is 42.46. The market cap for the company is $113,652m. You can visit the company’s website by visiting: https://www.gsk.com
The potential market cap would be $127,587m based on the market concensus.
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics; Alector; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences and Vir Biotechnology GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
